Jefferies Global Healthcare Conference
Logotype for UCB SA

UCB (UCB) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for UCB SA

Jefferies Global Healthcare Conference summary

17 Nov, 2026

Portfolio growth and business development

  • BIMZELX patent protection runs to 2037; four additional growth drivers have patents into the early 2030s, supporting a growth agenda underway for two years.

  • Current assets could support growth after 2035 if successful; external additions in familiar disease areas can strengthen internal pillars and diversify long-term pipeline risk.

  • 2026 and likely 2027 focus remains on executing launches, while IMIDomics, Antengene, Neurona and Candid add early-stage capabilities and modalities in established therapeutic areas.

  • Business development is shifting toward disease biology and longer-term benefit, including cell therapy for severe epilepsy and T-cell engagers aimed at immune reset in autoimmune disease.

BIMZELX outlook

  • Management sees potential for at least EUR 7bn in peak sales, citing superiority versus four competitors across psoriasis and psoriatic arthritis, and 150,000 patients with strong treatment experience.

  • Broader uptake may take time as prescribing habits, guidelines, PBM rebates and step edits do not always reward clinical superiority; management expects these barriers to ease over time.

  • Management sees potential across psoriasis, psoriatic arthritis and hidradenitis suppurativa; HS is an early-stage opportunity with compelling data and a growing market.

  • HS assessment should account for standard-of-care comparison, efficacy criteria, disease severity, placebo response and antibiotic use in trials.

  • HS diagnosis averages seven years after symptoms; management aims for earlier treatment and expects market leadership based on its data.

Neurology and pipeline differentiation

  • Myasthenia gravis is a larger, specialty market than previously understood, with varied prescribing practices and uneven uptake of anti-FcRn and anti-C5 therapies across geographies and hospitals.

  • The portfolio includes one anti-FcRn and one anti-C5, enabling treatment choice by patient profile; potential BCMA x CD3 T-cell engagers could add options for patients with high IgG levels.

  • Neurona cell therapy targets very severe temporal lobe epilepsy, including patients who cannot access surgery, with the aim of reducing seizures and supporting cognitive and brain development.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from UCB